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EFFECTIVENESS OF CANEPHRON® N IN THE COMPLEX MANAGEMENT 
OF SUBCLINICAL GOUTY NEPHROPATHY 
S. I. Smiyan, M. V. Franchuk, R. R. Komorovsky 
I. HORBACHEVSKY TERNOPIL STATE MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
Background. The risk of chronic kidney failure increases by 3–10 times with the steady increasing of uric 
acid level in the blood. It is known that the protein fractions is closely correlated with the level of uric acid. 
Objective. Microalbuminuria and microglobulinuria are predictors of kidney damage. The study involved 
50 patients with gout who had never received preventive treatment of gouty nephropathy. We choosed Canephron 
N (Bionorica, Neumarkt, Germany) as a combined phytodrug with nephroprotective effect. All studied patients 
were men with obesity. 
Results. According to standard examination kidney damage haven’t been found, but laboratory tests on 
microproteinuria showed that the vast majority of patients have signs of subclinical gouty nephropathy. 
Conclusions. Canephron N in complex gout treatment helps to decrease uric acid level in the blood and 
increase its excretion.
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Introduction 
The term “gouty nephropathy” (GN) com­
prises all renal pathology that may occur in 
patients with gout, including urate nephro li­
thiasis, tophi in the renal parenchyma, glome­
rulosclerosis, arteriosclerosis with subsequent 
nephrosclerosis, interstitial nephritis and chro­
nic renal failure. Moreover, the use of non­
steroidal anti-inflammatory drugs (NSAIDs) for 
symptomatic treatment of patients with gout is 
associated with nephrotoxicity and may result 
in acute tubular necrosis, acute interstitial 
nephritis, proteinuria, hypertension, hyperka­
lemia [6, 13]. The prevalence of kidney damage 
in patients with gout ranges from 30 to 70%. 
Hence it is essential that patients with chronic 
gout receive therapy for prevention of GN 
without any (or with minimal) side effects and 
contraindications. For this purpose we have 
chosen a herbal based medicine – Canephron® 
N (Bionorica, Neumarkt, Germany) which is an 
approved medicinal product containing a fixed 
combination of centaury herb (Centaurium sp.), 
lovage root (Levisticum officinale Koch), and 
rosemary leaves (Rosmarinus officinalis L.) [19]. 
It has been available on the European market 
for more than 40 years. The drug has diuretic 
[12, 33], spasmolytic [1, 32], anti-inflammatory 
[11, 23, 29], antimicrobial [7, 8, 17], nephrop-
rotective [18] and hypouricemic [25] effects. 
Some clinical studies show a therapeutic benefit 
in patients with urinary tract infections [9, 21, 
26] and diabetic nephropathy [19].
Materials and Methods
We examined 50 patients with gout (all men), 
who were hospitalized in the Department of 
Rheumatology of Ternopil University Hos pital. 
The patients were not previously diagno sedor 
tested for GN, nor were previously tested for GN. 
All the patients underwent main labora tory and 
instrumental methods of inves tigation and some 
additional tests for micro albumin and microglo­
bulin levels in morning urine performed by means 
of ELISA method. Micro proteinuria means any 
manifestation of microalbuminuria (MA), micro-
globulinuria (MG) or their combina tions. The 
patients were divi ded into 2 groups: the patients 
of group I (n=25), the study group, received 
standard urate lowering therapy (Allo pu rinol), 
NSAIDs for pain control and Cane phron® N; the 
patients of group II (n=25), the control group, 
received only Allopurinol and NSAIDs. Body mass 
index (BMI), plasma and urine uric acid (UA) 
levels, blood creatinine, urea and glomerular 
filtration rate (GFR) were tested. Kidney ultra-
sound and joint x­ray were also per for med. 
Ca ne phron® N was prescribed, 2 tablets 3 times 
per day for 6 weeks. After 6 weeks pati ents’ micro-
albumin, microglobulin levels in urine and UA 
levels in plasma and urine were re­examined. 
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Continuous variables are expressed as 
mean±standard error of the mean. Differences 
between the variables were determined by 
unpaired or paired t-test, as appropriate. A 
value of p<0,05 was considered to be statistically 
significant.
Results and Discussion
Baseline indicators of the examinations are 
presented in Table 1. Due to the BMI, the ma-
jority of patients in both groups were diagnosed 
with obesity. Blood creatinine level, urea and 
GFR were uninformative, because the findings 
were normal in both groups. Also nephrolithiasis 
was found in both groups. Laboratory and 
instrumental investigations showed that a 
significant proportion of the patients had 
subclinical GN (fig. 1).
In the study group 48% patients had MA 
and 60% of them had MG. In the control group 
44% patients had MA and 52% of them had MG. 
The patients from the study group received a 
combined treatment (Allopurinol, NSAIDs + 
Canephron N) and had better test results than 
the group which received standard treatment 
(Allopurinol, NSAIDs) (Table 2).
The pathogenesis of GN is associated with 
hyperproduction of UA and imbalance between 
the processes of its tubular secretion and 
reabsorption. But currently there is no enough 
evidence that hyperuricemia (HU) is a marker 
of renal dysfunction or a risk factor for kidney 
disorders. The controversial results of the 
impact of HU on development of chronic kidney 
disease (CKD) are, partly, due to difficulties in 
diagnosis of GN at the early stage because of 
a long subclinical period [5, 10, 24, 27].
Hyperproduction of UA and its excretion 
decrease leads to HU. The risk of chronic kidney 
Table 1. Baseline indicators
Markers Study group(n=25)
Control group
(n=25) p-value
Age, (yrs) 54,98±1,22 50,63±1,19 <0,05
Disease duration, (yrs) 8,96±0,57 7,42±1,43 >0,05
BMI 28,64±0,61 30,62±1,37 >0,05
Creatinine, (mmol/L) 72,12±0,39 78,31±1,21 >0,05
Urea, (mmol/L) 5,05±0,65 4,96±0,27 >0,05
GFR, ml/min 130,88±1,22 129,64±0,31 >0,05
Uric acid in plasma, (mcmol/L) 0,556±0,08 0,552±0,12 >0,05
X-ray stage, (%) I II III I II III –
11,4 79,5 9,1 11,8 76,5 11,7
Nephrolithiasis, (%) 28 36 –
p – significant differences between the baseline indicators of the study and control groups.
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Fig. 1. Microproteinuria in patients suffering from gout.
Table 2. Dynamics of changes at the beginning of the study and after 6 weeks of combined 
treatment with Canephron n and standard therapy (the study group),  
and standard therapy only (the control group)
Study group (n = 25) Control group (n = 25)
Markers Baseline After treatment Baseline
After 
treatment p-value
Microalbuminuria, (mg/L) 131,81±3,45 62,38±2,99* 114,72±3,91 122,19±2,11 <0,05
Microglobulinuria, (mg/L) 20,08±2,06 13,37±3,32* 22,36±3,12 21,19±2,94 <0,05
Uric acid in plasma, (mcmol/L) 0,556±0,08 0,457±0,06* 0,562±0,12 0,498±0,23** <0,05
Uric acid in urine, (mmol/L/day) 5,21±1,18 6,72±1,34* 5,02±1,09 5,08±1,02 <0,05
p – significant differences between the post-treatment markers of the study and control groups; 
* – after treatment in comparison with baseline markers of the study group (p<0,05); 
** – after treatment in comparison with baseline markers of the control group (p<0,05).
S. I. Smiyan et al.
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failure (CKF) rises in 3–10 times caused by 
increase in UA in blood. Every 4th patient has 
CRF as a gout complication [3, 4, 5, 22]. Several 
studies have shown relations of HU to the signs 
of kidneys damage [30, 31]. Also UA can affect 
renal hemodynamics due to vasoconstriction 
in cortical layer and increase the expression of 
renin. An additional mechanism in kidneys 
damage is the UA impact on the formation of 
the endothelial dysfunction by increasing 
monocyte chemoattractant protein-1 (MCP-1) 
in vascular smooth muscle fibres and cells of 
the proximal renal tubules. MCP-1 is a main 
pathogenetic chemokine of CKD and athero-
sclerosis [16].
It is established that the protein fraction is 
closely correlated with the level of UA in blood; 
that is why HU causes endothelial dysfunction 
and MA [2]. If albumins and other highmolecular 
weight proteins are found in urine, glomerular 
injury is present. Microglobulins (β2-, α1- and 
retinol-binding protein), MG, are tubular dis-
orders characterized by low-molecular weight 
proteins in urine. MA and MG are predictors of 
kidneys damage [14, 15, 19, 20, 28]. Reference 
limits of MA and MG are presented in table 3.
Conclusions
Microalbuminuria and microglobulinuria 
are the main early symptoms of renal damage 
in patients with gout. The prevalence of kidney 
damage is significantly (p<0,05) higher than the 
incidence of gouty nephropathy in clinical 
practice. Blood creatinine level, urea and GFR 
are uninformative at the stage of GN formation, 
which is asymptomatic. GN was diagnosed in 
64% patients of the study group and in 56% 
ones of the control group according to the 
levels of MA and MG. Uncontrolled hyper-
uricemia, which does not reach the target level, 
is a major risk factor for development of GN. 
The group of the patients who received Cane-
phron N as a standard gout treatment had 
better results after re-examination. This herbal 
based medicine has uricosuric effect because 
it decreases UA level in plasma. Microproteinuria 
decreased in 2 times after the combined treat-
ment with Canephron N. Also we did not detect 
any side effects during 6 weeks of the study. 
So, Canephron N is recommended for treatment 
of subclinical gouty nephropathy.
Table 3. Reference limits of microalbuminuria 
and microglobulinuria
Type Indicators (mg/L)
Normoalbuminuria <20
Microalbuminuria 20–200
Macroalbuminuria >200
Normoglobulinuria <12
Micro- and macroglobulinuria >12
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